Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Xetra  >  Siemens    SIE   DE0007236101

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets

Siemens AG : WSJ BLOG/Health : Siemens Sees Resurgence in Diagnostics as a Cost Cutter

share with twitter share with LinkedIn share with facebook
share via e-mail
04/13/2012 | 07:02pm CET

(This story has been posted on The Wall Street Journal Online's Health Blog at http://blogs.wsj.com/health.)

By Shirley S. Wang

The Health Blog caught up at TEDMED with Gregory Sorensen, chief executive of Siemens Healthcare in North America, to talk about the changing health-care field and what it means for diagnostics, an area in which Siemens is a player.

"We're beginning to see resurgence in diagnostics as a way to save costs, " Sorensen, formerly a radiology professor at Harvard Medical School, told the Health Blog.

A missed diagnosis is a big cost driver in health care because it wastes time and money on ineffective therapy, he said, pointing to an example of studies in Alzheimer's showing that upon autopsy, some 15%-20% of patients examined had a different ailment than believed and would have been treated differently when they were alive.

Of course, there's been an outcry about the unnecessary use of medical tests and Sorensen acknowledges there has been overuse in the past. Reductions in Medicare reimbursement rates have curbed overuse, he says, though not everyone agrees on that, as the Health Blog reported last week. The important thing now, Sorensen says, is to make sure people are getting the right diagnostic tests, rather than reduce the absolute number of them.

He recalled being a doctor in training in the late 1980s, when his professors taught him that, because of the risks associated with appendicitis, doctors should be conservative whenever a patient reported pain in the lower right quadrant of the abdomen. A good surgeon, therefore, would do exploratory surgery on five patients for every one that actually had appendicitis. Sorensen himself had his appendix -- which turned out to be healthy -- removed during this era.

Now patients get scanned if they report such pain, resulting in many fewer unnecessary surgeries, said Sorensen.

Siemens recognizes how important it is to demonstrate effectiveness in today's health-care business, and that payers want to see results, says Sorensen. As for the shift to reimbursement for value, "that train has left the station."

 -For continuously updated news from The Wall Street Journal, see WSJ.com at http://wsj.com. 

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on SIEMENS
11:26a German industrial employers aim for labour deal by early February
08:02a SIEMENS : Patent Issued for Measurement of Radio Frequency Excitation Pulses (US..
07:09a SIEMENS : Patent Issued for Reduction of Coupling Effects between Coil Elements ..
01:13a SIEMENS : Patent Issued for Medical Examination Facility (USPTO 9861326)
12:43a SIEMENS : Patent Issued for Combined Shim and RF Coil Arrangement (USPTO 9864023..
01/18 Daimler, Bosch hit by walkouts in sector-wide labour dispute
01/18 Chemical industry in bid to harness Germany's green power overload
01/18 SIEMENS : and Evonik to Develop Artificial Photosynthesis Plant
01/18 SIEMENS : Evonik and Siemens to generate high-value specialty chemicals from car..
01/17 Rolls-Royce shares jump as commercial marine business goes on block
More news
News from SeekingAlpha
01/16 Siemens (SIEGY) Investor Presentation - Slideshow
01/16 Siemens (SIEGY) Investor Presentation - Slideshow
01/15 Siemens - The 'German General Electric'
01/10 Siemens (SIEGY) Presents At Commerzbank German Investment Seminar 2018 - Slid..
01/02 SIEMENS : All Change, To What Effect?
Financials (€)
Sales 2018 84 864 M
EBIT 2018 8 512 M
Net income 2018 5 787 M
Debt 2018 18 164 M
Yield 2018 3,10%
P/E ratio 2018 17,33
P/E ratio 2019 15,65
EV / Sales 2018 1,45x
EV / Sales 2019 1,35x
Capitalization 105 B
Duration : Period :
Siemens Technical Analysis Chart | SIE | DE0007236101 | 4-Traders
Technical analysis trends SIEMENS
Short TermMid-TermLong Term
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 27
Average target price 130 €
Spread / Average Target 6,0%
EPS Revisions
Josef Kaeser President & Chief Executive Officer
Gerhard Cromme Chairman-Supervisory Board
Ralf Peter Thomas Chief Financial Officer
Roland Emil Busch Chief Technology Officer
Helmuth Ludwig Chief Information Officer
Sector and Competitors
1st jan.Capitalization (M$)
SIEMENS5.90%128 180
3M5.41%146 466